Hematology Briefings™: The Evolving Management Landscape for Patients With Sickle Cell Disease: Opportunities, Challenges, and Emerging Agents for Therapy

Released On
December 28, 2018

Expires On
December 28, 2019

Media Type
Internet

Completion Time
60 minutes

Specialty
Hematology

Topic(s)
Sickle Cell Disease

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians' Education Resource®, LLC.

 

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This continuing medical education (CME) activity is intended for hematologists and physicians including pediatricians, who manage patients with sickle cell disease. Nurse practitioners, nurses, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with sickle cell disease will be invited to participate.

Statement of Need/Program Overview

This activity, Hematology Briefings™: The Evolving Management Landscape for Patients With Sickle Cell Disease: Opportunities, Challenges, and Emerging Agents for Therapy, developed in Physicians’ Education Resource, LLC, (PER®) established Hematology Briefings™ legacy format, is an online interactive monograph that provides treatment strategies for patients with sickle cell disease (SCD). This presentation features a national thought leader, Laura DeCastro, MD, who provides key insights.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with SCD and vaso-occlusive (VOC) symptoms earlier to initiate prompt intervention and preventive therapy
  • Recognize the acute and chronic complications associated with VOC phenomena in SCD
  • Distinguish current and emerging treatments for management of SCD and VOC crises and best practices for their use in patients’ management
  • Better utilize shared-decision making as a regular part of patients’ management of SCD, including discussion of therapy options and choices

Faculty

Laura M. De Castro, MD, MHSc

Clinical Director benign Hematology
Associate Professor
Division of Hematology and Oncology
Department of Internal Medicine
UPMA
Pittsburgh, Pennsylvania

Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians and is a provider approved by the California Board of Registered Nursing (CBRN).

Credit Designation Statement

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ and for 1.0 contact hours for nurses. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The following contributors have relevant financial relationships with commercial interests to disclose:

Laura M. De Castro, MD, MHSc

  • Grant/Research Support: Bayer, Global Blood Therapeutics, Ironwood Pharmaceuticals, Pfizer
  • Consultant: Pfizer

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade) and program evaluation. Certificates can be printed immediately.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclaimer/Disclosure of Unlabeled Use

This activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.